Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001472375-25-000013
Filing Date
2025-02-07
Accepted
2025-02-07 12:21:26
Documents
45
Period of Report
2024-12-31

Document Format Files

Seq Description Document Type Size
1 QUARTERLY REPORT FOR THE PERIOD ENDED DECEMBER 31, 2024 ixform10q.htm   iXBRL 10-Q 462366
2 CERTIFICATION exhibit31-1.htm EX-31.1 11443
3 CERTIFICATION exhibit31-2.htm EX-31.2 11440
4 CERTIFICATION exhibit32-1.htm EX-32.1 4499
5 CERTIFICATION exhibit32-2.htm EX-32.2 4434
6 regenerexlogo.gif GRAPHIC 5716
  Complete submission text file 0001472375-25-000013.txt   2561255

Data Files

Seq Description Document Type Size
7 SCHEMA DOCUMENT rgpx-20241231.xsd EX-101.SCH 25064
8 CALCULATION LINKBASE DOCUMENT rgpx-20241231_cal.xml EX-101.CAL 33010
9 DEFINITION LINKBASE DOCUMENT rgpx-20241231_def.xml EX-101.DEF 122957
10 LABELS LINKBASE DOCUMENT rgpx-20241231_lab.xml EX-101.LAB 186393
11 PRESENTATION LINKBASE DOCUMENT rgpx-20241231_pre.xml EX-101.PRE 160582
47 EXTRACTED XBRL INSTANCE DOCUMENT ixform10q_htm.xml XML 196950
Mailing Address 5348 VEGAS DRIVE, SUITE 177 LAS VEGAS NV 89108
Business Address 5348 VEGAS DRIVE, SUITE 177 LAS VEGAS NV 89108 305-927-5191
REGENEREX PHARMA, INC. (Filer) CIK: 0001357878 (see all company filings)

EIN.: 980479983 | State of Incorp.: NV | Fiscal Year End: 0331
Type: 10-Q | Act: 34 | File No.: 000-53230 | Film No.: 25600442
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)